CN1742793A - Medicine composition and use thereof - Google Patents
Medicine composition and use thereof Download PDFInfo
- Publication number
- CN1742793A CN1742793A CN 200510098809 CN200510098809A CN1742793A CN 1742793 A CN1742793 A CN 1742793A CN 200510098809 CN200510098809 CN 200510098809 CN 200510098809 A CN200510098809 A CN 200510098809A CN 1742793 A CN1742793 A CN 1742793A
- Authority
- CN
- China
- Prior art keywords
- rhizoma chuanxiong
- danshensu
- total phenols
- chuanxiong total
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a medicine composite formed from ligusticum total phenol extract and danshensu (a salvia root extract) according to weight ratio of 1:9-9:1. Said medicine composite can be used for preventing and curing angiocardiopathy and serebrovascular diseases. Besides, said invention also provides its preparation method.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and purposes of forming by Rhizoma Chuanxiong total phenols extract and danshensu in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease thereof.
Background technology
Rhizoma Chuanxiong is the dry rhizome of samphire Rhizoma Chuanxiong (Ligusticm chuanxiong Hort.), its phenolic constituent has effect [Beijing Pharmaceutical Ind. Inst. such as tangible coronary artery dilating, increase hat flow, reduction myocardial oxygen consumption, the research of Rhizoma Chuanxiong effective ingredient. Acta Pharmaceutica Sinica, 1979 14 11 phases of volume].
Danshensu is the water soluble ingredient of Radix Salviae Miltiorrhizae, has antiplatelet aggregation, antithrombotic formation, microcirculation improvement and anti-oxidative damage effect and multipath performance myocardium protecting action.
The inventor is by a large amount of experimentatioies, a kind of pharmaceutical composition and application of being made up of Rhizoma Chuanxiong total phenols extract and danshensu in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease thereof is provided, and this pharmaceutical composition has synergism when preparation treatment or prevention cardiovascular and cerebrovascular disease.
Summary of the invention
The invention provides a kind of pharmaceutical composition of forming by Rhizoma Chuanxiong total phenols extract and danshensu, wherein the weight ratio of Rhizoma Chuanxiong total phenols extract (in the Rhizoma Chuanxiong total phenols) and danshensu is 1: 9～9: 1, be preferably 1: 4～4: 1, Rhizoma Chuanxiong total phenols＜100% in 50%≤Rhizoma Chuanxiong total phenols extract.
In the pharmaceutical composition provided by the invention, ferulaic acid content is not less than 50% in the Rhizoma Chuanxiong total phenols, and content of Danshensu is not less than 90%, and ferulic acid and danshensu can also exist with the form of slaine, are preferably sodium salt.
The invention provides the application of pharmaceutical composition in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease of forming by Rhizoma Chuanxiong total phenols extract and danshensu.
The invention provides the application of this pharmaceutical composition in the medicine of preparation treatment or prevention of brain apoplexy.
The invention provides the application of this pharmaceutical composition in preparing treatment or prevention coronary heart disease, anginal medicine.
Pharmaceutical composition provided by the invention is when being used for preparation treatment or prevention of brain apoplexy and coronary heart disease, angina pectoris, and its using dosage scope is 35mg～1050mg/ days, preferred 100mg～350mg/ days.
Pharmaceutical composition provided by the invention can add corresponding adjuvant according to the preparation needs, exists with tablet, pill, granule, capsule, suspension, solution, syrup, injection, chewing agent or patch form, is preferably freeze-dried powder.Various dosage form provided by the invention all can adopt the pharmacy conventional method to be prepared from.
Rhizoma Chuanxiong total phenols extract of the present invention can by [Xu Xiangyi is etc. the preferred Rhizoma Chuanxiong total phenols of orthogonal experiment extract extraction process for Wang Wenxiang, Gu Ming. 22 05 phases of volume of Chinese patent medicine .2000] described method extraction separation obtains.Danshensu of the present invention is that extraction separation obtains from Radix Salviae Miltiorrhizae, preferably adopts water extracting method, with macroporous adsorbent resin column chromatography method exquisiteness, obtains danshensu.
The present invention confirms the effect in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease of the pharmaceutical composition be made up of Rhizoma Chuanxiong total phenols extract and danshensu by following test, Rhizoma Chuanxiong total phenols extract and danshensu have synergism in the compositions when treatment or prevention cardiovascular and cerebrovascular disease.
The specific embodiment:
Preparation example 1: the preparation of Rhizoma Chuanxiong total phenols extract, danshensu
Rhizoma Chuanxiong total phenols extract by [Xu Xiangyi is etc. the preferred Rhizoma Chuanxiong total phenols of orthogonal experiment extraction process for Wang Wenxiang, Gu Ming. 22 05 phases of volume of Chinese patent medicine .2000] described method extraction separation obtains, and is further refining then.Regulate pH to alkalescence with NaOH, filter, concentrated freeze-dried, promptly get the Rhizoma Chuanxiong total phenols extract that contains sodium ferulate, wherein sodium ferulate content is 50.5%.
Medical material Radix Salviae Miltiorrhizae 50kg is extracted with 0.4% sodium hydroxide 1200L solution, obtain to contain the extracting solution of danshensu; Extracting solution is adjusted to neutrality with hydrochloric acid, adsorb with the adsorption column of having filled alkalescence macroporous adsorbent resin D301M, after treating that adsorbent is saturated, with alcoholic solution 50% (V/V) 400L eluting, 500L carries out eluting with sodium hydrate aqueous solution 0.4% (m/V), collect eluent, be concentrated into about 20L, transferring to pH value with hydrochloric acid is 2, carries out acid condition (pretreatment, it is 2 that the resin of handling well is eluted to the eluent pH value with hydrochloric acid solution) absorption with the adsorption column of having filled low pole adsorbent A B-8, pure water 800L eluting, collect eluent, concentrate, obtain concentrated solution 2L; Add sodium hydroxide 500g in the concentrated solution, cooling is left standstill, and obtains the danshensu sodium crystalline solid, filter, and washing, drying obtains danshensu sodium crystalline solid 322g, detects through HPLC, and purity reaches 94%.
Preparation example 2: the freeze-dried powder that preparation is made up of Rhizoma Chuanxiong total phenols extract and danshensu
Under cleaning condition, get the Rhizoma Chuanxiong total phenols extract, the danshensu 60g that contain Rhizoma Chuanxiong total phenols 60g, be dissolved in 1000ml water for injection, add 100g mannitol, stirring and dissolving, ultrafiltration, obtain apyrogenic clear liquor, pour in the 5ml cillin bottle, 1ml/ props up, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Rhizoma Chuanxiong total phenols 60mg, danshensu 60mg.
Preparation example 3: the freeze-dried powder that preparation is made up of Rhizoma Chuanxiong total phenols extract and danshensu
Under cleaning condition, get the Rhizoma Chuanxiong total phenols extract, the danshensu 80g that contain Rhizoma Chuanxiong total phenols 40g, be dissolved in 1000ml water for injection, add the 100g low molecular dextran, stirring and dissolving, ultrafiltration, obtain apyrogenic clear liquor, pour in the 5ml cillin bottle, 1ml/ props up, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Rhizoma Chuanxiong total phenols 40mg, danshensu 80mg.
Preparation example 4: the freeze-dried powder that preparation is made up of Rhizoma Chuanxiong total phenols extract and danshensu
Under cleaning condition, get the Rhizoma Chuanxiong total phenols extract, the danshensu 75g that contain Rhizoma Chuanxiong total phenols 25g, be dissolved in 1000ml water for injection, stirring and dissolving, ultrafiltration obtains apyrogenic clear liquor, pour in the 5ml cillin bottle, 1ml/ props up, and presses the lyophilizing of freeze-dried powder technology, makes the freeze-dried powder that contains Rhizoma Chuanxiong total phenols 25mg, danshensu 75mg.
Test example 1: the influence that various dose Rhizoma Chuanxiong total phenols extract, danshensu, compositions are damaged the rat local cerebral ischemia
(1) material:
Rhizoma Chuanxiong total phenols extract, danshensu, compositions: by preparation example 1 preparation.
Red tetrazolium: U.S. Sigma company product, face with preceding and be made into 4% solution with normal saline.
Laboratory animal: regular grade SD rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), nimodipine group (Nim, 1.0mg/kg), Rhizoma Chuanxiong total phenols extract small dose group is (in the Rhizoma Chuanxiong total phenols, down together) (1.5mg/kg), dosage group (3.5mg/kg) in the Rhizoma Chuanxiong total phenols extract, the heavy dose of group of Rhizoma Chuanxiong total phenols extract (45mg/kg), danshensu small dose group (2mg/kg), dosage group (3.5mg/kg) in the danshensu, the heavy dose of group of danshensu (60mg/kg), compositions low dose [Rhizoma Chuanxiong total phenols extract (1.5mg/kg)+danshensu (2mg/kg)], dosage in the compositions [Rhizoma Chuanxiong total phenols extract (15mg/kg)+danshensu (20mg/kg)], compositions heavy dose [Rhizoma Chuanxiong total phenols extract (45mg/kg)+danshensu (60mg/kg)], 10 every group.After the fasting 12 hours, and chloral hydrate (350mg/kg, i.p.) anesthesia separates right carotid, and folder closes in the neck, common carotid artery, external carotid artery proximal part and distal end ligation, cut off the centre.The external carotid artery free-end is pulled to internal carotid artery in alignment, bolt line (selecting diameter 0.24mm nylon wire for use, length 5.0cm) is inserted into intracranial by external carotid artery, stop when meeting slight resistance, insertion depth is about 2cm.Ligation external carotid artery opening, and open the common carotid artery bulldog clamp, the disinfection and stitching wound causes right side middle cerebral artery ischemia model; Sham operated rats is only carried out the separation (above experiment is all carried out at 23 ℃～25 ℃) of right carotid, internal carotid artery, external carotid artery.Each treated animal intravenous injection relative medicine of postoperative.Press document [Liu Xiaoguang, Xu Lina, a kind of rat brain medium-sized artery model that can estimate thrombolytic and anti-thrombolytic after 24 hours, Acta Pharmaceutica Sinica, 1995,30:662] described method and standard is observed and the behavior disorder of record rat: (A) carry the Mus tail and observe forelimb flexing situation, stretch to ground as two forelimb symmetries, count 0 fen, the wrist flexing occurs as operation offside forelimb and count 1 fen, the elbow flexing is counted 2 fens, the shoulder inward turning is counted 3 fens, existing wrist flexing and/or elbow flexing have shoulder inward turning person again, count 4 fens.(B) animal is placed on the plane earth, push away both shoulders respectively, check resistance to side shifting.As bilateral resistance equity and strong, count 0 fen, as resistance descender when the operation offside promotes, according to decline degree difference be divided into gently, in, weigh three degree, count 1,2 and 3 fen respectively.(C) the two forelimbs of animal are put on the wire netting, observed the muscular tension of two forelimbs.Two muscle of anterior limb tension force equities and strong person count 0 fen.Count 1,2 and 3 fen according to operation offside muscular tension decline degree difference equally.(D) animal has ceaselessly to a side person of turn-taking, and counts 1 fen.According to the standard scoring, full marks are 11 minutes, and mark is high more, and expression animal behavior obstacle is serious more.Put to death rat behind the behavior scoring, get brain, remove olfactory bulb, cerebellum and low brain stem, crownly be cut into 5, the brain sheet takes on a red color after normal structure is dyed with red tetrazolium (TTC) dyeing, and blocking tissue is white in color, taking a picture in dyeing back, asks the infarct size ratio with Chinese Aero-Space university pathological image analysis software.Data are represented with x ± SD, carry out statistical procedures with F check between group.
The result is as shown in table 1, and ischemia is after 24 hours, and the model group rat shows tangible behavior disorder, and tangible kitchen range shape ischemic region also appears in rat cerebral tissue, reaches about 25% of full brain.1.5mg/kg Rhizoma Chuanxiong total phenols extract and 2mg/kg danshensu group are failed to improve the rat behavior obstacle, are reduced ischemic areas; 3.5mg/kg Rhizoma Chuanxiong total phenols extract and 3.5mg/kg danshensu group have all been improved the rat behavior obstacle to a certain extent, have been reduced ischemic areas.Compositions small dose group [Rhizoma Chuanxiong total phenols extract (1.5mg/kg)+danshensu (2mg/kg)] is improved the rat behavior obstacle very significantly, is reduced ischemic areas, compare P＜0.01 with model group, and significant difference (P＜0.05) is more also arranged with 3.5mg/kg Rhizoma Chuanxiong total phenols extract, 3.5mg/kg danshensu.Illustrate that Rhizoma Chuanxiong total phenols extract and danshensu have synergism in the compositions.Compositions heavy dose [Rhizoma Chuanxiong total phenols extract (45mg/kg)+danshensu (60mg/kg)] is improved the rat behavior obstacle extremely significantly, is reduced ischemic areas, compares P＜0.001 with model group.
The influence that table 1 Rhizoma Chuanxiong total phenols extract, danshensu, compositions are damaged the rat local cerebral ischemia
| Group | Behavior disorder | Ischemic areas (%) |
| Dosage composition is heavy dose of in the heavy dose of group of the dosage group danshensu composition small dose group composition in the total phenol extraction thing heavy dose of the dosage group Ligusticum wallichii group danshensu small dose group danshensu in the total phenol extraction thing of sham-operation group model control group Nim group Ligusticum wallichii total phenol extraction thing small dose group Ligusticum wallichii organizes | 0 11.50±1.31 7.15±2.66 ** 10.22±3.16 8.80±1.07 * 6.86±3.17 ** 10.03±3.58 8.79±2.42 * 6.58±1.96 ** 6.67±2.35 **#Δ 6.27±2.41 *** 5.03±1.55 *** | 0 25.41±4.22 17.33±5.68 ** 22.38±8.95 19.23±2.45 * 12.91±4.32 ** 23.14±6.27 19.56±3.75 * 12.37±4.48 ** 13.34±7.56 **#Δ 11.54±5.32 *** 10.22±2.56 *** |
Compare with model control group
*P＜0.05,
*P＜0.01,
* *P＜0.001;
Compare #P＜0.05 with dosage group in the Rhizoma Chuanxiong total phenols extract; Compare with dosage group in the danshensu
ΔP＜0.05.
Test example 2: different proportioning pharmaceutical compositions are to the influence of rat local cerebral ischemia damage
(1) material:
Rhizoma Chuanxiong total phenols extract, danshensu, compositions: by preparation example 1 preparation.
Red tetrazolium: U.S. Sigma company product, face with preceding and be made into 4% solution with normal saline.
Laboratory animal: regular grade SD rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), compositions A[Rhizoma Chuanxiong total phenols extract is (in the Rhizoma Chuanxiong total phenols, down together) (10mg/kg)+danshensu (0mg/kg)], compositions B[Rhizoma Chuanxiong total phenols extract (9mg/kg)+danshensu (1mg/kg)], compositions C[Rhizoma Chuanxiong total phenols extract (8mg/kg)+danshensu (2mg/kg)], compositions D[Rhizoma Chuanxiong total phenols extract (5mg/kg)+danshensu (5mg/kg)], compositions E[Rhizoma Chuanxiong total phenols extract (2mg/kg)+danshensu (8mg/kg)], composition F [Rhizoma Chuanxiong total phenols extract (1mg/kg)+danshensu (9mg/kg)], compositions G[Rhizoma Chuanxiong total phenols extract (0mg/kg)+danshensu (10mg/kg)], 10 every group.Make rat local cerebral ischemia model and carry out neural behavior scoring, the dyeing of brain sheet by method shown in the experimental example 1.Data are represented with x ± SD, carry out statistical procedures with F check between group.
The result is as shown in table 2, and ischemia is after 24 hours, and the model group rat shows tangible behavior disorder, and tangible kitchen range shape ischemic region also appears in rat cerebral tissue, reaches about 25% of full brain.The pharmaceutical composition (10mg/kg) of different proportionings all has significant protective effect (P＜0.05 or P＜0.01) to rat cerebral ischemia.
The different proportioning pharmaceutical compositions of table 2 are to the influence of rat local cerebral ischemia damage
| Group | Behavior disorder | Ischemic areas (%) |
| Sham-operation group model control group composition A composition B composition C composition D composition E composition F composition G | 0 10.6±1.1 9.1±1.2 * 8.4±1.1 ** 7.0±0.8 **# Δ 7.2±0.7 **# Δ 7.1±0.9 **# Δ 8.5±0.8 * 8.9±0.7 * | 0 25.6±4.5 22.9±2.1 * 22.5±2.1 * 18.2±1.8 **# Δ 20.1±1.4 **# Δ 21.2±1.3 **# Δ 22.3±1.6 * 22.6±1.1 * |
Compare with model control group
*P＜0.05,
*P＜0.01;
Compositions A group is #P＜0.05 relatively; Compositions G organizes relatively
ΔP＜0.05
Test example 3: Rhizoma Chuanxiong total phenols extract, danshensu, Rhizoma Chuanxiong total phenols extract and danshensu compositions are to the influence of rat heart muscle ischemic injuries
(1) material:
Rhizoma Chuanxiong total phenols extract, danshensu, compositions: by preparation example 1 preparation.
Painstaking effort pellet (compound Salviae Miltiorrhizae) injection: Guizhou Shenqi Pharmaceutical Co., Ltd.
Chlorination nitro blue tetrazolium (N-BT) is provided by Military Medical Science Institute medical supply station.
Laboratory animal: regular grade Wistar rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), FUFANG DANSHEN ZHUSHEYE group (DS, 10mg/kg), Rhizoma Chuanxiong total phenols extract small dose group is (in the Rhizoma Chuanxiong total phenols, down together) (1.5mg/kg), dosage group (3.5mg/kg) in the Rhizoma Chuanxiong total phenols extract, the heavy dose of group of Rhizoma Chuanxiong total phenols extract (45mg/kg), danshensu small dose group (2mg/kg), dosage group (3.5mg/kg) in the danshensu, the heavy dose of group of danshensu (60mg/kg), compositions low dose [Rhizoma Chuanxiong total phenols extract (1.5mg/kg)+danshensu (2mg/kg)], dosage in the compositions [Rhizoma Chuanxiong total phenols extract (15mg/kg)+danshensu (20mg/kg)], 10 every group of compositions heavy doses [Rhizoma Chuanxiong total phenols extract (45mg/kg)+danshensu (60mg/kg)].After the fasting 12 hours, limbs II lead electrocardiogram is surveyed in ip urethane (1.2g/kg) anesthesia.Cut off left front fur, iodine tincture and alcohol disinfecting, along left border of sternum 1cm place, cut off thoracic wall muscle and two ribs, open the thoracic cavity rapidly, expose heart, the ligation left coronary artery is put back to heart immediately between arterial cone and left auricle, squeezes the thoracic cavity air, use the mosquito forceps closed-chest, cause Model Rats with Acute Myocardial Ischemia.Each treated animal intravenous injection relative medicine of postoperative.1.5h, 3h electrocardiogram before the record administration and after the administration take out heart behind the 6h, after cleaning with cold saline, and-20 ℃ of refrigerator freeze overnight.Next day, refrigerated heart is cut into 5 by ligation place to apex uniform thickness, immerse in the freshly prepared 0.5%NBT phosphate buffer (pH7.4).37 ℃ of water-bath jolting 10～15min.Blot the dyeing liquor of slice surface with filter paper, separate the coloured portions and the part of being unstained, weigh compute myocardial ischemia percentage ratio.Myocardial ischemia percentage ratio (%)=infarction part weight/(non-infarction part weight+infarction part weight) * 100%.
The result is as shown in table 3, and myocardial ischemia is after 6 hours, and tangible kitchen range shape ischemic region appears in the model group rat heart muscle, reaches about 25%.1.5mg/kg Rhizoma Chuanxiong total phenols extract and 2mg/kg danshensu group are failed to improve the rat electrocardio, are reduced ischemic areas; 3.5mg/kg Rhizoma Chuanxiong total phenols extract and 3.5mg/kg danshensu group all reduce rising, the minimizing ischemic areas of the limb lead electrocardiogram J point that is caused by myocardial ischemia to a certain extent; Compositions small dose group [Rhizoma Chuanxiong total phenols extract (1.5mg/kg)+danshensu (2mg/kg)] reduces rising, the minimizing ischemic areas of limb lead electrocardiogram J point very significantly, compare P＜0.01 with model group, and significant difference (P＜0.05) is more also arranged with 3.5mg/kg Rhizoma Chuanxiong total phenols extract, 3.5mg/kg danshensu; Compositions heavy dose [Rhizoma Chuanxiong total phenols extract (45mg/kg)+danshensu (60mg/kg)] reduces rising, the minimizing ischemic areas of limb lead electrocardiogram J point extremely significantly, compares P＜0.001 with model group.
Table 3 Rhizoma Chuanxiong total phenols extract, danshensu, compositions are to the influence of rat heart muscle ischemic injuries
| Grouping | Myocardial ischemia percentage ratio (%) | J point rising (mv/10) | ||
| Normally | 1.5h | 3h | ||
| Dosage group composition is heavy dose of in the heavy dose of group of the dosage group danshensu composition small dose group composition in the total phenol extraction thing heavy dose of the dosage group Ligusticum wallichii group danshensu small dose group danshensu in the total phenol extraction thing of the total phenol extraction thing of model control group danshen injections group Ligusticum wallichii small dose group Ligusticum wallichii organizes | 25.6±4.3 17.8±6.2 *22.5±8.5 19.4±3.5 *12.8±4.5 **23.3±6.4 19.7±3.5 *12.6±4.5 **13.6±7.8 **#Δ 12.1±3.8 **#Δ 10.5±2.7 *** | 0.8±0.6 0.8±0.6 0.7±0.6 0.7±0.5 0.7±0.7 0.8±0.7 0.7±0.6 0.8±0.6 0.8±0.5 0.8±0.5 0.7±0.6 | 6.7±2.3 6.0±1.5 * 6.5±1.3 5.8±1.4 * 5.0±1.6 ** 6.4±1.5 5.7±1.8 * 4.9±2.1 ** 4.7±1.6 **#Δ 4.2±1.2 *** 4.3±1.7 *** | 6.1±1.4 5.1±1.3 * 5.8±1.9 5.2±1.8 * 4.3±2.0 ** 5.7±2.1 5.1±1.7 * 4.1±1.8 ** 4.0±1.6 **#Δ 3.8±1.7 *** 3.7±1.9 *** |
Compare with model control group
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Compare #P＜0.05 with dosage group in the Rhizoma Chuanxiong total phenols extract
Compare Δ P＜0.05 with dosage group in the danshensu
Test example 4: different proportioning pharmaceutical compositions are to the influence of rat heart muscle ischemic injuries
(1) material:
Rhizoma Chuanxiong total phenols extract, danshensu, compositions: by preparation example 1 preparation.
Chlorination nitro blue tetrazolium (N-BT) is provided by Military Medical Science Institute medical supply station.
Laboratory animal: regular grade Wistar rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), compositions A[Rhizoma Chuanxiong total phenols extract is (in the Rhizoma Chuanxiong total phenols, down together) (10mg/kg)+danshensu (0mg/kg)], compositions B[Rhizoma Chuanxiong total phenols extract (9mg/kg)+danshensu (1mg/kg)], compositions C[Rhizoma Chuanxiong total phenols extract (8mg/kg)+danshensu (2mg/kg)], compositions D[Rhizoma Chuanxiong total phenols extract (5mg/kg)+danshensu (5mg/kg)], compositions E[Rhizoma Chuanxiong total phenols extract (2mg/kg)+danshensu (8mg/kg)], composition F [Rhizoma Chuanxiong total phenols extract (1mg/kg)+danshensu (9mg/kg)], compositions G[Rhizoma Chuanxiong total phenols extract (0mg/kg)+danshensu (10mg/kg)] 10 every group.The method shown in the experimental example 3 of pressing is made rat heart muscle ischemia model and calculating myocardium ischemia percentage ratio.Data are represented with x ± SD, carry out statistical procedures with F check between group.
The result is as shown in table 4, and ischemia is after 6 hours, and tangible kitchen range shape ischemic region appears in rat heart muscle, reaches about 25%.The pharmaceutical composition (10mg/kg) of different proportionings all has significant protective effect (P＜0.05 or P＜0.01) to the rat heart muscle ischemia.Compositions C, D, E and compositions A or G more all have significant difference (P＜0.05), and Rhizoma Chuanxiong total phenols extract and danshensu have synergism in the prompting compositions.
The different proportioning pharmaceutical compositions of table 4 are to the influence of rat heart muscle ischemic injuries
| Group | Ischemic areas (%) |
| Sham-operation group model control group composition A composition B composition C composition D composition E composition F composition G | 0 24.9±4.4 22.8±2.0 * 22.6±2.2 * 18.1±1.7 **# Δ 20.0±1.3 **# Δ 21.1±1.2 **# Δ 22.2±1.5 * 22.6±1.3 * |
Compare with model control group
*P＜0.05,
*P＜0.01.
Compare #P＜0.05 with compositions A group.
Compare with compositions G group
ΔP＜0.05.
Claims (9)
1. pharmaceutical composition of forming by Rhizoma Chuanxiong total phenols extract and danshensu, Rhizoma Chuanxiong total phenols extract (in the Rhizoma Chuanxiong total phenols) and danshensu weight ratio are 1: 9～9: 1, Rhizoma Chuanxiong total phenols＜100% in 50%≤Rhizoma Chuanxiong total phenols extract, wherein ferulaic acid content is not less than 50% in the Rhizoma Chuanxiong total phenols, and content of Danshensu is not less than 90%.
2. compositions according to claim 1, preferred proportion are 1: 4～4: 1.
3. compositions according to claim 1, ferulic acid and danshensu can also exist with the form of slaine.
4. compositions according to claim 3, slaine is preferably sodium salt.
5. the purposes of the arbitrary described pharmaceutical composition of claim 1-4 in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease.
6. the purposes of the arbitrary described pharmaceutical composition of claim 1-4 in the medicine of preparation treatment or prevention of brain apoplexy.
7. the purposes of the arbitrary described pharmaceutical composition of claim 1-4 in preparation treatment or prevention coronary heart disease, anginal medicine.
8. the described compositions of claim 1-4 is when preparation treatment or prevention cardiovascular and cerebrovascular disease, and its using dosage scope is 35mg～1050mg/ days.
9. the described compositions of claim 1-4 is when preparation treatment or prevention cardiovascular and cerebrovascular disease, its using dosage scope preferred 100～350mg/ days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510098809A CN100577184C (en) | 2004-09-02 | 2005-09-01 | Medicine composition and use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410035634 | 2004-09-02 | ||
| CN200410035634.7 | 2004-09-02 | ||
| CN200510098809A CN100577184C (en) | 2004-09-02 | 2005-09-01 | Medicine composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1742793A true CN1742793A (en) | 2006-03-08 |
| CN100577184C CN100577184C (en) | 2010-01-06 |
Family
ID=36138418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510098809A Expired - Fee Related CN100577184C (en) | 2004-09-02 | 2005-09-01 | Medicine composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100577184C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007009B (en) * | 2007-01-31 | 2010-05-19 | 首都医科大学 | A drug for preventing and treating liver injury and lowering blood fat |
| CN114642669A (en) * | 2020-12-18 | 2022-06-21 | 正大青春宝药业有限公司 | A senkyunolide I compound and its application in preparing medicines for treating thrombosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279936C (en) * | 2003-11-12 | 2006-10-18 | 北京金桥时代生物医药研究发展中心 | Medicine for treating coronary heart disease and angina pectoris and restenosis after intervention operation |
-
2005
- 2005-09-01 CN CN200510098809A patent/CN100577184C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007009B (en) * | 2007-01-31 | 2010-05-19 | 首都医科大学 | A drug for preventing and treating liver injury and lowering blood fat |
| CN114642669A (en) * | 2020-12-18 | 2022-06-21 | 正大青春宝药业有限公司 | A senkyunolide I compound and its application in preparing medicines for treating thrombosis |
| CN114642669B (en) * | 2020-12-18 | 2023-10-10 | 正大青春宝药业有限公司 | Senkyunolide I compound and application thereof in preparation of medicines treating thrombus diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100577184C (en) | 2010-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1349818A (en) | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process | |
| CN1701787A (en) | Application of Danshensu in preparation of medicine for treating cerebrovascular diseases | |
| CN101342274B (en) | Curculigo orchioides extract, preparation method and uses thereof | |
| CN101596182A (en) | Contain pharmaceutical composition, its preparation method, the purposes of salviol acid A and contain the lyophilized injectable powder and the aqueous injection of said composition | |
| CN1861122A (en) | Traditional Chinese medicine prepn. used for treating apoplexia and obstruction of qi in the chest, and its prepn. method | |
| CN100577184C (en) | Medicine composition and use thereof | |
| CN1736375A (en) | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN1626075A (en) | Combination of medication and application of preparing medication for treating or preventing cardiovascular and cerebrovascular diseases | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN1911219A (en) | Medicine composition, and its application for treating diseases of cardiovascular and cerebrovascular | |
| CN1686464A (en) | Radix dactylicapni injection and its preparation method | |
| CN1879614A (en) | A pharmaceutical composition and application thereof in treatment of cardiovascular and cerebrovascular disease | |
| CN1923803A (en) | Arginine rosmarinate, preparation method, pharmaceutical composition and use thereof | |
| CN1352985A (en) | Active component of red sage root, its slowly releasing medicine and medical purpose, and its preparing process | |
| CN100551372C (en) | A kind of pharmaceutical composition and the application in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease thereof | |
| CN103830220A (en) | Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases | |
| CN1785988A (en) | Saflor yellow pigment rich in saflor yellow pigment B, its preparation method and use | |
| JP4995727B2 (en) | Use of winter savory (SATUREJAMMONTANA) or its extract for the manufacture of a drug for the treatment of premature ejaculation | |
| CN1868507B (en) | Medicine composition, preparation method and application thereof | |
| CN1868508B (en) | Medicine composition, application of the same for preparing medicine to treat and prevent cardiovascular and cerebrovascular disease | |
| CN100346798C (en) | Traditional Chinese medicine active part composition for curing cardio and cerebral vascular disease and its preparing method | |
| CN100486578C (en) | Medicine composition and its application in preparation of medicine for treating or preventing cardiovascular and cerebrovascular diseases | |
| CN1283650C (en) | Process of extracting total flavone glycoside from mistletoe and medicine composition thereof | |
| CN101036640A (en) | Novel medical function of cnidium monnieri lactone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170608 Address after: 264670, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Patentee after: Shandong Luye Pharma Co., Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100106 Termination date: 20180901 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |